New drug combo aims to prevent transplant complications in blood cancer patients
NCT ID NCT03320642
First seen Nov 01, 2025 · Last updated May 12, 2026 · Updated 29 times
Summary
This early-stage study tested whether adding the drug itacitinib to standard anti-rejection medicines could safely prevent graft-versus-host disease (GVHD) in 84 people with blood cancers receiving a stem cell transplant. The main goal was to see if blood cell recovery was normal with the combination. The study was terminated early, so final results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOLOGIC MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Anschutz Cancer Pavilion - University of Colorado
Aurora, Colorado, 80045, United States
-
Azienda Ospedaliera San Gerardo Di Monza
Monza, 20900, Italy
-
Azienda Socio Sanitaria Territoriale Papa Giovanni Xxiii (Presidio Papa Giovanni Xxiii)
Bergamo, 24127, Italy
-
Centre Hospitalier Universitaire de Nantes (Chu de Nantes) - Hotel-Dieu
Nantes, 44093, France
-
Chru de Lille Hopital Claude Huriez
Lille, 59037, France
-
Chu Vandoeuvre-Les-Nancy, Hopital Brabois
Vandœuvre-lès-Nancy, 54500, France
-
Comitato Di Bioetica Della Fondazione Irccs Policlinico San Matteo
Pavia, 27100, Italy
-
Froedtert Hospital and the Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States
-
Hospital Clinico Universitario de Valencia
Valencia, 46010, Spain
-
Hospital Puerta de Hierro
Majadahonda, 28222, Spain
-
John Theurer Cancer Center, Hackensack University Medical Center
Hackensack, New Jersey, 07601, United States
-
Loyola University Medical Center
Maywood, Illinois, 60153, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
The Ohio State University
Columbus, Ohio, 43210, United States
-
University of Maryland - Greenebaum Cancer Center
Baltimore, Maryland, 21201, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
-
Winship Cancer Institute of Emory University
Atlanta, Georgia, 30322, United States
Conditions
Explore the condition pages connected to this study.